Metoclopramide Accord

Metoclopramide Hydrochloride Anhydrous, the active ingredient in Metoclopramide Accord, is a dopamine antagonist presented as an oral tablet for oral administration. Approved in the European Union, it is prescribed to manage nausea and vomiting, gastroparesis, gastro‑oesophageal reflux disease, and migraine‑associated nausea in adult patients.

GNH USA supplies Metoclopramide Accord as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics across global markets while adhering to stringent quality and regulatory standards and ensuring reliable delivery through efficient logistics.

Metoclopramide is an antiemetic and prokinetic agent that acts on the gastrointestinal tract and the chemoreceptor trigger zone.

Nausea and vomiting: reduces frequency and severity of episodes. Gastroparesis: accelerates gastric emptying and improves related symptoms. Gastro‑oesophageal reflux disease: decreases reflux episodes and associated discomfort. Migraine‑associated nausea: controls nausea accompanying migraine attacks.

Metoclopramide may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Drowsiness: feeling of sleepiness or reduced alertness. - Fatigue: general tiredness. - Restlessness: inner sense of unease or agitation. - Diarrhea: loose or frequent stools.

Serious or Rare Side Effects: - Extrapyramidal reactions: acute dystonia, akathisia, or parkinsonism. - Tardive dyskinesia: irreversible involuntary movements with long‑term use. - Neuroleptic malignant syndrome: life‑threatening hyperthermia and muscle rigidity. - Severe depression or suicidal thoughts: marked mood changes.

Before prescribing Metoclopramide, clinicians should consider several safety measures.

Renal function assessment: adjust use in patients with severe renal impairment. Elderly monitoring: watch for increased risk of extrapyramidal symptoms. Hypersensitivity: discontinue if allergic reactions occur. Concurrent CNS depressants: use cautiously as additive sedation may occur. Pregnancy category B1: consider risk‑benefit, use only if clearly needed. Store at room temperature: keep in the original packaging, protect from moisture and light.

Metoclopramide can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): additive dopamine blockade may precipitate severe extrapyramidal effects. - Monoamine oxidase inhibitors: risk of hypertensive crisis and serotonin syndrome. - CNS depressants (opioids, benzodiazepines): enhanced sedation and respiratory depression. - Strong CYP2D6 inhibitors (e.g., fluoxetine): increase metoclopramide plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may reduce pro‑kinetic efficacy. - Selective serotonin reuptake inhibitors: potential for serotonin syndrome, monitor symptoms. - Tricyclic antidepressants: may increase risk of cardiac effects. - Digoxin: possible alteration of serum levels.